Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 2/2016

Open Access 01-06-2016 | Review

Systemic Treatment of Pediatric Psoriasis: A Review

Authors: Maddalena Napolitano, Matteo Megna, Anna Balato, Fabio Ayala, Serena Lembo, Alessia Villani, Nicola Balato

Published in: Dermatology and Therapy | Issue 2/2016

Login to get access

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1–3% of the white population. Although the existence of two psoriasis incidence peaks has been suggested (one in adolescence before 20 years of age and another in adulthood), its onset may occur at any age, including childhood and adolescence, in which the incidence is now estimated at 40.8 per 100,000. As for adult psoriasis, pediatric psoriasis has recently been associated with obesity, metabolic syndrome, increased waist circumference percentiles and metabolic laboratory abnormalities, warranting early monitoring and lifestyle modifications. In addition, due to psoriasis' chronic nature and frequently occurring relapses, psoriatic patients tend to have an impaired quality of life, often requiring long-term treatment. Therefore, education of both pediatric patients and their parents is essential to successful and safe disease management. Given the lack of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, to date, pediatric psoriasis treatment is primarily based on published case reports, case series, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders coming from the disciplines of rheumatology, gastroenterology and oncology. This review focuses on the use of systemic treatments in pediatric psoriasis and their specific features, analyzing the few literature evidences available, expanding the treatment repertoire and guiding dermatologists in better managing of recalcitrant pediatric psoriasis.
Literature
1.
Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143:1559–65.PubMedCrossRef
2.
Megna Matteo, Napolitano Maddalena, Balato A, et al. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11:10–26.CrossRef
3.
Sticherling M, Augustin M, Boehncke WH, et al. Therapy of psoriasis in childhood and adolescence— a German expert consensus. J Dtsch Dermatol Ges. 2011;9:815–23.PubMed
4.
Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62:979–87.PubMedCrossRef
5.
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394–401.PubMedPubMedCentralCrossRef
6.
Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17:174–8.PubMedCrossRef
7.
Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:1–18.PubMedCrossRef
8.
9.
Smith CH, Anstay VA, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019.PubMedCrossRef
10.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74.PubMedCrossRef
11.
12.
Cordoro KM. Systemic and light therapies for the management of childhood psoriasis: part II. Skin Therapy Lett. 2008;13:1–3.
13.
Holme SA, Anstey AV. Phototherapy and PUVA photochemotherapy in children. Photodermatol Photoimmunol Photomed. 2004;20:69–75.PubMedCrossRef
14.
Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133:1514–22.PubMedCrossRef
15.
Lara-Corrales I, Ramnarine S, Lansang P. Treatment of childhood psoriasis with phototherapy and photochemotherapy. Clin Med Insights Pediatr. 2013;7:25–33.PubMedPubMedCentralCrossRef
16.
Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20:71–7.PubMedCrossRef
17.
18.
Kopp T, Karlhofer F, Szépfalusi Z, Schneeberger A, Stingl G, Tanew A. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004;151:912–6.PubMedCrossRef
19.
Marqueling A, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin. 2013;31:267–88.PubMedCrossRef
20.
Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. 2011;25:727–9.PubMedCrossRef
21.
Wong Y, Koh MJ, Chong WS. Role of narrowband ultraviolet B phototherapy in the treatment of childhood psoriasis in Asian children. Pediatr Dermatol. 2015;32:e221–3.PubMedCrossRef
22.
23.
Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13:406–9.PubMedCrossRef
24.
Jain VK, Aggarwal K, Jain K, Bansal A. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46:320–2.PubMedCrossRef
25.
Zamberk P, Velazquez D, Campos M, Hernanz JM, Lázaro P. Paediatric psoriasis: narrowband UVB treatment. J Eur Acad Dermatol Venereol. 2010;24:415–9.PubMedCrossRef
26.
27.
Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14:195–213.PubMedCrossRef
28.
Charbit L, Mahé E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2015. doi:10.​1111/​bjd.​14326. [Epub ahead of print].
29.
Zweegers J, de Jong EM, Nijsten TE, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dermatol Online J. 2014;20:1–112.
30.
Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005;6:1725–34.PubMedCrossRef
31.
de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62:1013–30.PubMedCrossRef
32.
Lacour M, Mehta-Nikhar B, Atherton DJ, Harper JI. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol. 1996;134:1023–9.PubMedCrossRef
33.
Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003;49:171–82.PubMedCrossRef
34.
Katugampola RP, Finlay AY. Oral retinoid therapy for disorders of keratinization: single-centre retrospective 25 years’ experience on 23 patients. Br J Dermatol. 2006;154:267–76.PubMedCrossRef
35.
Halverstam CP, Zeichner J, Lebwohl M. Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. J Cutan Med Surg. 2006;10:291–9.PubMedCrossRef
36.
Van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangx NM, Kuijpers AL, Van de Kerkhof PC. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol. 1996;134:71–6.PubMedCrossRef
37.
McMullen EA, McCarron P, Irvine AD, Dolan OM, Allen GE. Association between long-term acitretin therapy and osteoporosis: no evidence of increased risk. Clin Exp Dermatol. 2003;28:307–9.PubMedCrossRef
38.
de Oliveira ST, Maragno L, Arnone M, Fonseca Takahashi MD, Romiti R. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010;27:349–54.PubMedCrossRef
39.
Xiao T, Li B, He CD, Chen HD. Juvenile generalized pustular psoriasis. J Dermatol. 2007;34:573–6.PubMedCrossRef
40.
Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15:144–6.PubMedCrossRef
41.
Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26:352–4.PubMedCrossRef
42.
Salleras M, Sanchez-Regana M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol. 1995;12:231–4.PubMedCrossRef
43.
Judge MR, McDonald A, Black MM. Pustular psoriasis in childhood. Clin Exp Dermatol. 1993;18:97–9.PubMedCrossRef
44.
Ergin S, Ersoy-Evans S, Sahin S, Ozkaya O. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatol Treat. 2008;19:341–3.CrossRef
45.
46.
Liao PB, Rubinson R, Howard R, Sanchez G, Frieden IJ. Annular pustular psoriasis: most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19:19–25.PubMedCrossRef
47.
Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol. 2008;33:551–4.PubMedCrossRef
48.
Paller AS. Dermatologic uses of methotrexate in children: indications and guidelines. Pediatr Dermatol. 1985;2:238–43.PubMedCrossRef
49.
Chládek J, Grim J, Martínková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54:147–56.PubMedPubMedCentralCrossRef
50.
Wright NA, Piggott CD, Eichenfield LF. The role of biologics and other systemic agents in the treatment of pediatric psoriasis. Semin Cutan Med Surg. 2010;29:20–7.PubMedCrossRef
51.
Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824–37.PubMedCrossRef
52.
Ståhle M, Atakan N, Boehncke WH, et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges. 2010;8:812–8.PubMed
53.
Gisondi P, Fantuzzi F, Malerba M, Girolomoni G. Folic acid in general medicine and dermatology. J Dermatolog Treat. 2007;18:138–46.PubMedCrossRef
54.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1–70.PubMedCrossRef
55.
Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25:184–8.PubMedCrossRef
56.
van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Systemic treatments in paediatric psoriasis: a systematic evidence based update. J Eur Acad Dermatol Venereol. 2015;29:425–37.PubMedCrossRef
57.
Van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatol Treat. 2015;20:1–7.
58.
Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31:430–9.PubMedCrossRef
59.
Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15(2):144–6.PubMedCrossRef
60.
Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11:271–3.PubMedCrossRef
61.
Dogra S, Handa S, Kanwar AJ. Methotrexate in severe childhood psoriasis. Pediatr Dermatol. 2004;21:283–4.PubMedCrossRef
62.
Dogra S, Kumaran MS, Handa S, Kanwar AJ. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol. 2005;22:85–6.PubMedCrossRef
63.
64.
Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed. 2011;9:190–1.PubMed
65.
Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34:295–8.PubMedCrossRef
66.
Scott RB, Surana R. Erythrodermic psoriasis in childhood: a young Negro child treated with methotrexate. Am J Dis Child. 1968;116:218–21.PubMedCrossRef
67.
Alli N, Gόngφr E, Karakayali G, Lenk N, Artόz F. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139:754–5.PubMedCrossRef
68.
Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatolog Treat. 2003;14:113–8.PubMedCrossRef
69.
Pereira TM, Vieira AP, Fernandes JC, Sousa-Basto AJ. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol. 2006;20:651–6.PubMedCrossRef
70.
Kiliç SS, Hacimustafaogˇlu M, Celebi S, Karadeniz A, Ildirim I. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18:246–8.PubMedCrossRef
71.
Mahé E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137:1532.PubMed
72.
Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41:S25–8.PubMedCrossRef
73.
Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649–61.PubMedCrossRef
74.
75.
Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23:306–8.PubMedCrossRef
76.
Nakamura S, Hashimoto Y, Igawa S, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol. 2009;34:e1023–4.PubMedCrossRef
77.
Bulbul Baskan E, Yazici S, Tunali S, Saricaoglu H. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis. J Dermatolog Treat. 2015:1–4 [Epub ahead of print].
78.
Di Lernia V, Stingeni L, Boccaletti V, et al. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis. J Dermatolog Treat. 2015;10:1–4.CrossRef
79.
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs. 1983;26:9–43.PubMedCrossRef
80.
Namba C, Murakami M, Hanakawa Y, et al. Infantile generalized pustular psoriasis: successful disease control with intermittent etretinate. J Dermatol. 2014;41:403–6.PubMedCrossRef
81.
Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123:230–3.PubMedCrossRef
82.
Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol. 1997;36:266–7.PubMedCrossRef
83.
Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years. Pediatr Dermatol. 2012;29:206–8.PubMedCrossRef
84.
Rosińska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5:266–72.PubMedCrossRef
85.
Rood MJ, Lavrijsen SP, Huizinga TW. Acitretin-related ossification. J Rheumatol. 2007;34:837–8.PubMed
86.
Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;11:43–8.PubMedCrossRef
87.
van Geel MJ, van de Kerkhof PC, Oostveen AM, de Jong EM, Seyger MM. Fumaric acid esters in recalcitrant pediatric psoriasis: a prospective, daily clinical practice case series. J Dermatolog Treat. 2016;27:214–20.PubMedCrossRef
88.
Balak DM, Oostveen AM, Bousema MT, et al. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands. Br J Dermatol. 2013;168:1343–7.PubMedCrossRef
89.
Reich K, Hartl C, Gambichler T, Zschocke I. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges. 2016;14:50–7.PubMed
90.
Steinz K, Gerdes S, Domm S, Mrowietz U. Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre. Dermatology. 2014;229(3):199–204.PubMedCrossRef
91.
Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299:111–38.PubMedPubMedCentralCrossRef
92.
Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis—best use of biologics. Expert Rev Clin Immunol. 2014;10:269–79.PubMedCrossRef
93.
Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X. Anti-TNF agents for paediatric psoriasis. Cochrane Database Syst Rev. 2015;11:CD010017.PubMed
94.
Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241–51.PubMedCrossRef
95.
Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63:762–8.PubMedCrossRef
96.
Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794–804.PubMedCrossRef
97.
98.
Paller AS, Siegfried EC, Langley RG, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280–7.PubMedCrossRef
99.
100.
Campione E, Diluvio L, Terrinoni A, et al. Severe erytrodermic psoriasis in child twins: from clinical-pathological diagnosis to treatment of choice through genetic analyses: two case reports. BMC Res Notes. 2014;7:929.PubMedPubMedCentralCrossRef
101.
Fraga NA, Paim Mde F, Follador I, et al. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011;86:S144–7.PubMedCrossRef
102.
Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87–8.PubMedCrossRef
103.
Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11:11.PubMed
104.
Rott S, Kuster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol. 2007;157:191–2.PubMedCrossRef
105.
Tsang V, Dvorakova V, Enright F, Gleeson C. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015. (doi:10).
106.
Skrabl-Baumgartner A, Weger W, Salmhofer W, et al. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32(1):13–4.CrossRef
107.
Luu M, Cordoro KM. The evolving role of biologics in the treatment of pediatric psoriasis. Skin Therapy Lett. 2013;18:1–4.PubMed
108.
Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365–74.PubMedCrossRef
109.
Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthal. 2007;91:319–24.CrossRef
110.
Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16:350–2.CrossRef
111.
Alvarez AC, Rodriguez-Nevado I, De Argila D, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol. 2011;28:195–7.PubMedCrossRef
112.
Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol. 2013;93:588–9.PubMedCrossRef
113.
114.
Fotiadou C, Lazaridou E, Giannopoulou C, Ioannides D. Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis. Eur J Dermatol. 2011;21:117–8.PubMed
115.
AbuHilal M, Ho N. Successful treatment of severe psoriasis in an adolescent with ustekinumab. Pediatr Dermatol. 2015;32:377–80.PubMedCrossRef
116.
Dixit S, Shumack S, Fischer G. Ustekinumab in the treatment of severe paediatric psoriasis. Aust J Dermatol. 2013;54:147.CrossRef
117.
Landells I, Colleen Marano, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594–603.PubMedCrossRef
118.
119.
120.
Jaleel T, Elmets C, Weinkle A, et al. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016;9:187–202.PubMedCrossRef
121.
Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134–42.PubMedCrossRef
Metadata
Title
Systemic Treatment of Pediatric Psoriasis: A Review
Authors
Maddalena Napolitano
Matteo Megna
Anna Balato
Fabio Ayala
Serena Lembo
Alessia Villani
Nicola Balato
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2016
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0117-6

Other articles of this Issue 2/2016

Dermatology and Therapy 2/2016 Go to the issue

Erratum

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Original Research

Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict

Original Research

A 10-Year Retrospective Analysis of Methyl Aminolevulinate Photodynamic Therapy Consultation at the Hospital de Braga

Original Research

CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation

Review

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Original Research

How People with Facial Acne Scars are Perceived in Society: an Online Survey

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits